SYRE · NASDAQ · STOCK
Spyre Therapeutics (SYRE) Stock Analysis
$85.72
52W $18.12 – $110.18
61/100
$7.44B
-43.9
3.11
Is SYRE Bullish or Bearish?
Bullish.
Innellis AI committee rates Spyre Therapeutics, Inc. (SYRE) Buy with a composite score of 61/100
, based on 6 analysts with 67% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +14.17 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -5.83 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Growth Analyst sees a compelling case — quarter-over-quarter growth rate is accelerating, not just positive. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
Bear Case
- ROE of only -24.3% -- cheap may mean cheap for a reason — Value
- MACD histogram negative -- bearish momentum — Technical
- Bollinger bandwidth of 19.2% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
61/100
Agreement
67%
Analysts
6
Conviction
Moderate
Sector Rank
Top 29%
of 192 Healthcare peers
Value Analyst
neutral
52
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− ROE of only -24.3% -- cheap may mean cheap for a reason
Growth Analyst
bullish
85
/ 100 · Low confidence
Strong, accelerating growth with consistent execution
+ Quarter-over-quarter growth rate is ACCELERATING, not just positive
Technical Analyst
neutral
48
/ 100 · High confidence
Mixed or range-bound price action
− MACD histogram negative -- bearish momentum
Risk Analyst
neutral
58
/ 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
+ Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock
− Bollinger bandwidth of 19.2% signals elevated volatility
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
neutral
58
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 59.2 to 60.8.
- Conviction changed from contested to moderate.
- Committee agreement increased notably from 50% to 67%.
- New bearish signals: 1 appeared.
- Bearish pressure eased: 2 signal(s) disappeared.
- Analyst(s) changed stance: Technical Analyst.
Analyst-level changes:
- Risk Analyst: +1 bearish signal(s).
- Technical Analyst: stance bearish->neutral; score 38->48 (+10).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
47.9
Neutral
MACD Histogram
-0.324
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Lh Ll
Support
$64.75
Resistance
$110.14
Bollinger %B
0.36
Inside Bands
Price vs Moving Averages
EMA 9
$85.37
Above
EMA 21
$87.84
Below
EMA 50
$90.46
Below
EMA 200
$72.70
Above
Fundamental Analysis
Valuation
74
Growth
85
Profitability
0
Financial Health
100
Cash Flow
15
Valuation
P/E Ratio
-43.9×
P/B Ratio
6.59×
PEG Ratio
0.86
Dividend Yield
0.00%
52W High
$110.18
52W Low
$18.12
Quality & Growth
ROE
-2170.0%
ROA
-1995.5%
Gross Margin
0.0%
Operating Margin
-22249.0%
Revenue Growth YoY
—
Debt / Equity
0.00
AI Fundamental Assessment
P/E ratio of -43.9 (inexpensive relative to a 15-40x range); Price-to-book of 6.6x; PEG ratio of 0.9 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -21.7%; Return on assets of -20.0%; Net margin of -197.7%; Gross margin of 0.0%; Current ratio of 18.53 (healthy short-term liquidity); Debt-to-equity of 0.00; Free cash flow per share is negative (-2.47); Most recent quarter beat estimates by 53.5%; EPS growth accelerating (-5.7% -> +51.4% QoQ); Analyst estimates rising over recent quarters
Get the Full SYRE Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →